Grants for Independent school districts - Federal

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports small-scale brain imaging research related to substance use and addiction, aimed at helping both new and established researchers develop innovative studies that enhance our understanding of neurobiological mechanisms in these areas.

This funding opportunity supports research teams from various sectors to explore how sex differences influence the biological factors related to Alzheimer’s disease and its treatment, aiming to enhance understanding and improve precision medicine approaches.

The Administration for Children and Families (ACF) is soliciting applications for Secondary Analyses of Head Start Data awards. These awards aim to support researchers conducting secondary analyses of data of relevance to Head Start (HS) programs and policies. This includes research of relevance to HS programs serving families with children 3 to 5 years old, Early HS programs serving pregnant women and families with infants and toddlers, American Indian Alaska Native (AI/AN) HS programs serving families in tribal communities, and Migrant and Seasonal HS programs serving families engaged in migrant and seasonal farm work. The goals of the awards are to: 1) Address topics of current relevance to the goals and outcomes of HS programs; 2) Encourage active communication, networking, and collaboration among prominent HS researchers and policymakers; and 3) Increase the capacity of HS researchers to analyze existing data sets and disseminate their findings to multiple audiences. Topics and data sets of particular interest will be identified in the Notice of Funding Opportunity. Findings from these awards are intended to inform policy, program administration, and future research. If you are interested in this funding opportunity, please register at Grants.gov and subscribe to this forecast to receive update notifications.

This grant provides funding for innovative and high-risk technology development projects in biomedical research that are in the early exploratory stages and have not yet been proven feasible.

The U.S. Department of Energys (DOE) Office of Energy Efficiency and Renewable Energy (EERE) Building Technologies Office (BTO) is issuing this Funding Opportunity Announcement (FOA) titled Bipartisan Infrastructure Law (BIL): Resilient and Efficient Codes Implementation (RECI). The current FOA represents the second installment in the RECI initiative, which maintains the same broad format, flexibility, and crosscutting areas of interest, while emphasizing and prioritizing specific gaps, needs, and opportunities to support building energy codes identified as focal points through the first RECI FOA and continued stakeholder engagement. The activities to be funded under the FOA support the BIL, as well as a broader government-wide approach to advance building codes and support their successful implementation. The primary focus centers around updating to more efficient building energy codes that save money for American homes and businesses, reduce greenhouse gas (GHG) emissions, and encourage more resilient buildings. This FOA includes one topic area broadly focused on the cost-effective implementation of updated energy codes.

This grant provides funding for innovative and high-risk research projects in biomedical, behavioral, or clinical fields, aimed at early-stage ideas that could lead to significant advancements.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This funding opportunity provides financial support to rural healthcare organizations in the Delta region to improve service delivery, enhance sustainability, and expand access to care through specific projects.

The BLM Arizona Cultural Heritage Partnership Program (CHPP) supports projects advancing the Department of Interior's priorities, including addressing the climate crisis, restoring balance on public lands, advancing environmental justice, and investing in a clean energy future. Projects should focus on public archaeology education, the development of educational programs, repatriation of Native American remains, and cultural resource inventory. Eligible applicants include higher education institutions, non-profits, state and local governments, and Indian tribal governments. The program aims to support projects that use science, data, and traditional knowledge to enhance economic opportunities for communities of color, low-income families, and rural and indigenous communities.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRCs). These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research community. A goal of this Centers program is to support important and innovative research in the muscular dystrophies that is best pursued through an interdisciplinary and collaborative center environment and projects that may not be as effective if supported by "stand-alone" research project grants. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Finally, Center investigators are expected to engage the patient and advocacy communities in conversations to increase awareness of research, encourage patient participation in research, and incorporate the perspectives of these communities in the conduct of patient-centered research.

This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as liquid biopsies", or other biospecimens as described in this FOA. Extramural research funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for "liquid biopsies", tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

The "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer" grant aims to fund preliminary research into how the human microbiome affects the body's immune response to cancer, with a focus on how specific microbes or their byproducts can either increase or prevent tumor formation, and how the amount, timing, and duration of beneficial microbes can impact their effectiveness.

This funding opportunity supports the development of a national data resource center to improve research on childhood cancers and congenital anomalies, encouraging collaboration among a wide range of organizations and researchers.

This funding opportunity provides financial support for educational programs that train new researchers in Down syndrome to improve understanding and treatment of co-occurring health conditions throughout the lifespan.

This grant provides funding for researchers at U.S. institutions to explore innovative uses of nanotechnology in cancer research, focusing on improving targeted delivery and diagnostic capabilities for specific cancer types.

This funding opportunity supports research institutions and organizations in developing and testing new treatments and recovery methods for individuals with alcohol use disorder, particularly focusing on underserved populations and innovative approaches.

Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 7, 2022. Purpose of Program: The purpose of the Disability Innovation Fund (DIF) Program, as provided by the Consolidated Appropriations Act, 2023 (Pub. L. 117-328), is to support innovative (as defined in this notice) activities aimed at increasing competitive integrated employment (CIE) as defined in section 7 of the Rehabilitation Act of 1973 (Rehabilitation Act) (29 U.S.C. 705(5))[1] for youth and other individuals with disabilities. Assistance Listing Number (ALN) 84.421F. [1] See 34 CFR 361.5(c)(9) for the regulatory definition of "competitive integrated employment," which further clarifies the definition in the Rehabilitation Act.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI R01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of enhancing their original research and speeding up scientific discoveries in cancer research.

This funding opportunity provides financial support to organizations working in Zambia to improve HIV and TB prevention, care, and treatment services through innovative and sustainable quality improvement strategies.